Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab.

Mattei TA, Ramos E, Rehman AA, Shaw A, Patel SR, Mendel E.

Spine J. 2014 Jul 1;14(7):e15-21. doi: 10.1016/j.spinee.2014.02.019. Epub 2014 Feb 15.

PMID:
24534393
2.

Giant cell tumors of the spine: has denosumab changed the treatment paradigm?

Goldschlager T, Dea N, Boyd M, Reynolds J, Patel S, Rhines LD, Mendel E, Pacheco M, Ramos E, Mattei TA, Fisher CG.

J Neurosurg Spine. 2015 May;22(5):526-33. doi: 10.3171/2014.10.SPINE13937. Epub 2015 Feb 20.

PMID:
25700239
3.

Interest of Denosumab for the Treatment of Giant-cells Tumors and Aneurysmal Bone Cysts of the Spine. About Nine Cases.

Dubory A, Missenard G, Domont J, Court C.

Spine (Phila Pa 1976). 2016 Jun;41(11):E654-60. doi: 10.1097/BRS.0000000000001350.

PMID:
27244112
4.

Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.

Wojcik J, Rosenberg AE, Bredella MA, Choy E, Hornicek FJ, Nielsen GP, Deshpande V.

Am J Surg Pathol. 2016 Jan;40(1):72-80. doi: 10.1097/PAS.0000000000000506.

PMID:
26414220
5.

Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.

Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I.

Clin Cancer Res. 2012 Aug 15;18(16):4415-24. doi: 10.1158/1078-0432.CCR-12-0578. Epub 2012 Jun 18.

6.

Giant cell tumor of the cervical spine: a series of 22 cases and outcomes.

Junming M, Cheng Y, Dong C, Jianru X, Xinghai Y, Quan H, Wei Z, Mesong Y, Dapeng F, Wen Y, Bin N, Lianshun J, Huimin L.

Spine (Phila Pa 1976). 2008 Feb 1;33(3):280-8. doi: 10.1097/BRS.0b013e318162454f.

PMID:
18303460
7.

Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy.

Matcuk GR Jr, Patel DB, Schein AJ, White EA, Menendez LR.

Skeletal Radiol. 2015 Jul;44(7):1027-31. doi: 10.1007/s00256-015-2117-5. Epub 2015 Feb 26.

PMID:
25712768
8.

A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab.

Aponte-Tinao LA, Piuzzi NS, Roitman P, Farfalli GL.

Clin Orthop Relat Res. 2015 Sep;473(9):3050-5. doi: 10.1007/s11999-015-4249-2. Epub 2015 Mar 11. Review.

9.

Denosumab: a new treatment option for giant cell tumor of bone.

Lewin J, Thomas D.

Drugs Today (Barc). 2013 Nov;49(11):693-700. doi: 10.1358/dot.2013.49.11.2064725. Review.

PMID:
24308016
10.

RANKL, denosumab, and giant cell tumor of bone.

Thomas DM.

Curr Opin Oncol. 2012 Jul;24(4):397-403. doi: 10.1097/CCO.0b013e328354c129. Review.

PMID:
22581354
11.
12.

Early evaluation of the therapeutic effect of denosumab on tartrate-resistant acid phosphatase 5b expression in a giant cell tumor of bone: a case report.

Watanabe N, Matsumoto S, Shimoji T, Ae K, Tanizawa T, Gokita T, Motoi N, Ueno T, Koizumi M.

BMC Res Notes. 2014 Sep 5;7:608. doi: 10.1186/1756-0500-7-608.

13.

Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases.

Deveci MA, Paydaş S, Gönlüşen G, Özkan C, Biçer ÖS, Tekin M.

Acta Orthop Traumatol Turc. 2017 Jan;51(1):1-6. doi: 10.1016/j.aott.2016.03.004. Epub 2016 Oct 24.

14.

Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.

Lau CP, Huang L, Wong KC, Kumta SM.

Connect Tissue Res. 2013;54(6):439-49. doi: 10.3109/03008207.2013.848202.

PMID:
24060052
15.

An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab.

Akaike K, Suehara Y, Takagi T, Kaneko K, Saito T.

Skeletal Radiol. 2014 Dec;43(12):1767-72. doi: 10.1007/s00256-014-1961-z. Epub 2014 Jul 24.

PMID:
25052539
16.

Vertebral compression fractures in patients under treatment with denosumab: a contraindication for percutaneous vertebroplasty?

Mattei TA, Mendel E, Bourekas EC.

Spine J. 2014 Jun 1;14(6):e29-35. doi: 10.1016/j.spinee.2013.11.046. Epub 2013 Dec 6.

PMID:
24316116
17.

Pathogenesis of Osteosclerotic Change Following Treatment with an Antibody Against RANKL for Giant Cell Tumour of the Bone.

Rosario M, Takeuchi A, Yamamoto N, Hayashi K, Miwa S, Higuchi T, Abe K, Taniguchi Y, Aiba H, Tanzawa Y, Murakami H, Tsuchiya H.

Anticancer Res. 2017 Feb;37(2):749-754.

PMID:
28179326
18.

[New therapy approaches for giant cell tumors].

Panzica M, Lüke U, Omar M, Länger F, v Falck C, Krettek C.

Unfallchirurg. 2014 Oct;117(10):883-91. doi: 10.1007/s00113-014-2580-9. German.

PMID:
25274386
19.

Effect of denosumab on recurrent giant cell reparative granuloma of the lumbar spine.

Akeda K, Kasai Y, Sakakibara T, Matsumine A, Takegami N, Yamada J, Sudo A.

Spine (Phila Pa 1976). 2015 May 15;40(10):E601-8. doi: 10.1097/BRS.0000000000000862.

PMID:
25955096
20.

Spondylectomy for Giant Cell Tumor After Denosumab Therapy.

de Carvalho Cavalcante RA, Silva Marques RA, dos Santos VG, Sabino E, Fraga AC Jr, Zaccariotti VA, Arruda JB, Fernandes YB.

Spine (Phila Pa 1976). 2016 Feb;41(3):E178-82. doi: 10.1097/BRS.0000000000001191.

Supplemental Content

Support Center